The objectives of this study are to evaluate the effectiveness of an antiperspirant in
preventing or attenuating the severity of palmer-plantar erythrodysesthesia associated with
the Food and Drug Administration (FDA)-approved doses of capecitabine. The hypothesis is that
cytotoxic compounds in sweat will be prevented from being deposited in the skin and causing
chronic toxicity.